Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Altria Group Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Altria Group Inc trades at $70.31 (market cap $120.02B). The key difference: Altria Group Inc is far larger — about 15× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Altria Group Inc pays a 5.9% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | MO | |
|---|---|---|
Market Cap | $8.02B | $120.02B |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $74.55 |
52-Week Low | $241.71 | $54.72 |
Enterprise Value | $7.84B | $141.09B |
Dividend Yield | — | 5.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MO trades at $71.87, up 0.14% today, with a neutral technical signal and bullish moving averages. The company reported a net income margin of 39.52% for 2025, with recent earnings beating expectations in Q1 2026. Strong cash flow from operations of $9.29B supports its dividend, with a recent $1.06 payment declared. Analyst consensus is bullish with a $71.00 price target.
Outlook remains stable with defensive qualities highlighted by media, but risks include high debt levels and regulatory pressures. The stock offers a high yield and pricing power, though revenue trends show slight volatility. Investment appeal centers on dividend sustainability and cash flow generation amid a challenging industry backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
